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Mammalian eggs are arrested in metaphase II of meiosis until fertilization. Arrest is maintained by cytostatic factor (CSF)
activity, which is dependent on the MOS–MEK–MAPK pathway. Inhibition of MEK1/2 with a specific inhibitor, U0126,
parthenogenetically activated mouse eggs, producing phenotypes similar to Mos/ parthenogenotes (premature, unequal
cleavages and large polar bodies). U0126 inactivated MAPK in eggs within 1 h, in contrast to the 5 h required after
fertilization, while the time course of MPF inactivation was similar in U0126-activated and fertilized eggs. We also found
that inactivation of MPF by the cdc2 kinase inhibitor roscovitine induced parthenogenetic activation. Inactivation of MPF
by roscovitine resulted in the subsequent inactivation of MAPK with a time course similar to that following fertilization.
Notably, roscovitine also produced some Mos/-like phenotypes, indistinguishable from U0126 parthenogenotes. Simul-
taneous inhibition of both MPF and MAPK in eggs treated with roscovitine and U0126 produced a very high proportion of
eggs with the more severe phenotype. These findings confirm that MEK is a required component of CSF in mammalian eggs
and imply that the sequential inactivation of MPF followed by MAPK inactivation is required for normal spindle function
and polar body emission. © 2002 Elsevier Science (USA)
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Ovulated eggs of many species, including mammals, are
arrested at metaphase II of meiosis (MII) until they are
fertilized. MII eggs are characterized by high activity of
maturation promoting factor (MPF), a complex of activated
cdc2 (cdk1) kinase and cyclin B that maintains the meta-
phase state (Taieb et al., 1997; Labbe et al., 1988; Abrieu et
al., 2001). In addition to high MPF activity, MII-arrested
eggs also exhibit a characteristic high ERK1/2 mitogen-
activated protein kinase (MAPK) activity (Verlhac et al.,
1993; Haccard et al., 1993; Abrieu et al., 2001). In eggs, the
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ohri.ca.210regulatory pathway upstream of ERK1/2 consists of MOS
kinase, which activates MEK, a specific regulator of ERK1/2
MAPK (Matsuda et al., 1992). The MOS–MEK–MAPK path-
way in oocytes is thought to be a required component of the
cytostatic factor (CSF) activity of eggs, which maintains
MPF activity and metaphase arrest and prevents the rela-
tively rapid reentry into interphase that follows metaphase
in somatic cells (Masui and Markert, 1971; Haccard et al.,
1993; Abrieu et al., 2001). This has been studied most
thoroughly in Xenopus oocytes, where MOS, MEK, and
MAPK have each been shown to be essential for CSF
activity and where p90rsk has recently been identified as a
downstream effector of the MAPK pathway in CSF activity
(Haccard et al., 1993; Bhatt and Ferrell, 1999; Gross et al.,
2000).
Although it has been clearly established that MOS, MEK,
and MAPK are each required components of CSF in Xeno-0012-1606/02 $35.00
© 2002 Elsevier Science (USA)
All rights reserved.
pus oocytes, only a requirement for MOS has thus far been
firmly established in mammals. Mos/ mouse oocytes
undergo germinal vesicle breakdown (GVBD) and progress
through the first meiosis normally, but fail to arrest in MII.
Instead, they undergo spontaneous parthenogenetic activa-
tion (Colledge et al., 1994; Hashimoto et al., 1994), thus
establishing a requirement for MOS activity in the mainte-
nance of MII arrest in the mouse. Similarly, inhibition of
MOS synthesis in mouse oocytes using RNA interference
also resulted in parthenogenetic activation (Wianny and
Zernicka-Goetz, 2000).
As in Xenopus and other nonmammalian species, it has
been shown that fertilization and release of MII arrest
in mammalian eggs induces the inactivation of MAPK
(Verlhac et al., 1994; Liu et al., 1998; Liu and Yang, 1999;
Tatemoto and Muto, 2001). While MAPK inactivation oc-
curs after MPF inactivation and thus does not mediate the
release from MII arrest, it does appear to regulate the
formation of pronuclei; maintaining high MAPK activity in
mouse eggs does not affect exit from metaphase II nor
second polar body emission but does prevent the develop-
ment of pronuclei (Moos et al., 1995, 1996b). Although
considerable similarity is evident between the functions of
the MAPK pathway in Xenopus and mammals, there are
nevertheless fundamental differences. For example, al-
though the activation of the MOS–MEK–MAPK pathway
around the time of GVBD is a feature of meiotic maturation
in both species, MAPK activation is required for GVBD to
occur in Xenopus oocytes (Ferrell, 1999; Abrieu et al., 2001),
while GVBD and meiotic maturation can occur normally in
mouse in the complete absence of MAPK activation (Colledge
et al., 1994; Hashimoto et al., 1994; Abrieu et al., 2001).
Mos/ oocytes not only activate spontaneously, but the
parthenogenotes also exhibit a distinctive set of pheno-
types, with a high proportion exhibiting abnormally large
polar bodies and/or unequal and premature cleavages (Hirao
and Eppig, 1997). The etiology of the distinctive Mos/
phenotypes is unknown, although it is thought to be due
specifically to the absence of MEK and MAPK activities in
the MII egg. Absence of MAPK activity in the mature MII
egg and during egg activation is thought to affect the
metaphase spindle and disrupt regulation of the unequal
cytokinesis which produces polar bodies. This is consistent
with results obtained in invertebrates such as Urechis
caupo, oyster, and starfish, where inhibition of MAPK
activity during fertilization results in large polar bodies and
abnormal spindles (Gould and Stephano, 1999; Stephano
and Gould, 2000), but it has not been directly tested in
mammals. An alternative explanation is that the lack of
MOS–MEK–MAPK activity during progression through
meiosis, rather than during MII arrest and egg activation,
prevents the development of a normal spindle or mecha-
nisms regulating cytokinesis in the mature MII egg.
We wished to determine whether MEK–MAPK activity
downstream of MOS is required to maintain MII arrest in
mouse oocytes, and whether perturbation of MEK and
MAPK activities in mature MII oocytes is sufficient to
cause abnormal spindle function and cytokinesis following
normal meiotic maturation and MII arrest in the presence
of MOS–MEK–MAPK activity. To do this, it was necessary
to perturb MEK and MAPK activities only in the mature
MII egg, following normal meiotic maturation and MII
arrest in the presence of an active MOS–MEK–MAPK path-
way. Thus, we have exploited the recent development of a
specific inhibitor of MEK1/2, U0126, which inhibits acti-
vated MEK (Favata et al., 1998), and an inhibitor of MPF,
roscovitine, which blocks activity of cdc2 kinase (Meijer et
al., 1997), to separately perturb MAPK and MPF activities
in mature mouse eggs.
MATERIALS AND METHODS
Chemicals
All components of media were embryo culture or cell culture
grade and were obtained from Sigma (St. Louis, MO) unless noted
otherwise. Hyaluronidase, equine chorionic gonadotropin (eCG),
human chorionic gonadotropin (hCG), EGTA (ethylene glycol-
bis[b-aminoethyl ether]-N,N,N,N,-tetraacetic acid),Tris–HCl,
leupeptin, PMSF (phenyl methylsulfonyl fluoride), roscovitine,
ATP, p-nitrophenylphosphate, -glycerophosphate, Na orthovana-
date, Na fluoride, DTT (dithiothreitol), aprotinin, PVA (polyvinyl
alcohol), MOPS (3-[N-morpholino]propane-sulfonic acid), histone,
Tween 20, Coomassie Blue, and mineral oil were obtained from
Sigma. U0126, U0124, Pepstatin, NP-40 (Nonidet P-40), and H-89
(N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide,
HCl) were obtained from Calbiochem (La Jolla, CA). U0126 and
U0124 were prepared as either a 5 mM or 50 mM stock in DMSO
stored at 20°C. Roscovitine was prepared as a 50 mM stock in
DMSO. Demecolcine was prepared as a 1-mg/ml stock in ethanol
and stored at 20°C. MgCl2 was obtained from VWR Canada (Ville
Mont-Royal, PQ). [-32P]ATP was obtained from Amersham (Baie
d’Urfe´, PQ). Myelin basic protein and 2 Laemmli sample buffer
were obtained from Invitrogen Canada, Inc. (Burlington, ON).
Solutions
All media were based on KSOM embryo culture medium (Lawitts
and Biggers, 1993). For handling eggs and zygotes, Hepes–KSOM (pH
7.4; Lawitts and Biggers, 1993) was used. For sperm capacitation and
in vitro fertilization (IVF), modified KSOM media was used with
glucose increased to 5.56 mM and 30 mg/ml fatty acid-free (FAF)–BSA
(IVF-KSOM; Summers et al., 1995; Phillips and Baltz, 1999).
Egg and Zygote Collection
Female CF1 mice (Charles River, Canada) were superovulated by
using 5 IU eCG (Sigma) followed 48 h later by 5 IU hCG (Sigma).
For zygotes, females were caged with BDF males following admin-
istration of hCG. Unfertilized eggs were collected 13.5–16 h
post-hCG, while zygotes were collected 20–22 h post-hCG. Where
appropriate, the cumulus was removed by exposure to 300 g/ml
hyaluronidase in Hepes–KSOM for 6–8 min (Hogan et al., 1986).
IVF
Sperm were obtained from CD-1 males (Charles River, Canada).
Capacitation and in vitro fertilization were as described previously
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(Phillips and Baltz, 1999). After 1 h, eggs were washed free of
unbound sperm and placed into KSOM microdrops. After fertiliza-
tion, activated eggs were selected for MAPK assays. Egg activation
was confirmed by the appearance of the second polar body and/or
pronuclei.
U0126 Treatment
Unfertilized eggs, denuded of cumulus cells, were transferred
into KSOM containing the specified concentration of U0126 (or the
inactive analog U0124) where appropriate. For control treatments,
unfertilized eggs were cultured in KSOM containing 0.1 or 0.2%
DMSO.
Roscovitine Treatment
Unfertilized eggs, denuded of cumulus cells, were transferred
into KSOM containing 50 M roscovitine. Because roscovitine
appears to be oil-soluble and thus is removed from culture droplets
if they are maintained under oil (data not shown), eggs were
cultured in 48-well culture plates (Nunc) in a volume of 500 l for
all experiments involving this drug. For some experiments, rosco-
vitine and U0126 were used in combination as specified.
Kinase Assays
MBP kinase assay (modified from Sobajima et al., 1993). Five
eggs or zygotes were lysed in 22 l of 50 mM Tris–HCl, 1% NP-40,
10 g/ml leupeptin, 100 g/ml PMSF, 5 mM EGTA, and 15 mM
MgCl2 and frozen at 80°C until use. The kinase reaction was
initiated by the addition of ATP, MBP, and [-32P]ATP to final
concentrations of 12 M, 136 g/ml, and 0.2 mCi/ml, respectively.
Reactions were carried out at room temperature for 15 min and
stopped by addition of 25 l 2 Laemmli sample buffer and boiling.
The mixtures were separated on 15% SDS–polyacrylamide gels
(SDS–PAGE), which were stained and fixed with Coomassie Blue,
and dried on filter paper.
Double kinase assay for simultaneous measurement of histone
H1 kinase (MPF) and MBP kinase (MAPK) activity (modified from
Moos et al., 1996a). Seven eggs or zygotes were lysed in 3.5 l
double kinase lysis buffer and frozen at 80°C until the kinase
assay was performed. The kinase reaction was initiated by the
addition of 5 l of double kinase buffer containing both MBP and
histone H1 as described previously (Moos et al., 1996a). The
reaction was carried out at room temperature and was stopped after
30 min by the addition of 10 l 2 Laemmli sample buffer,
followed by boiling. The mixtures were separated and fixed as
above.
For the MBP and double kinase assays, a sample of freshly
obtained eggs and zygotes were assayed as positive and negative
controls, respectively. Scanning and quantification of the signal
were performed by using a Typhoon 8600 variable mode imager
(Molecular Dynamics, Sunnyvale, CA) and ImageQuant software
(Molecular Dynamics). Signals were corrected for background by
subtracting the density in the marker lane (MBP kinase assay) or by
subtracting the density of a control reaction mix which did not
contain eggs or zygotes (double kinase assay). The values of histone
H1 or MBP kinase activity for fresh eggs (MBP kinase and double
kinase assays) or for egg lysates exposed to vehicle during the
kinase reaction (when drug added to kinase assay) were arbitrarily
set at 100%. The values obtained in the other groups were
expressed relative to this value.
Immunodetection of Phospho-MAPK
Thirty or forty eggs/zygotes were lysed in 15 l of lysis buffer
containing 20 mM Tris–HCl (pH 7.5), 100 mM NaCl, 0.5% Triton
X-100, 0.5% NP-40, 1 mM PMSF, and 1 g/ml each of leupeptin
and pepstatin followed by the addition of an equal volume of 2
Laemmli sample buffer and boiling (Kanatsu-Shinohara et al.,
2000). Proteins in the lysate were separated by SDS–PAGE and
semidry transferred onto Protran pure nitrocellulose membrane
(Scheicher & Schuel, Keene, NH). The membrane was incubated
with primary antibody sheep polyclonal IgG anti-phospho-MAPK
(Upstate Biotechnology, Lake Placid, NY) followed by secondary
antibody peroxidase-conjugated AffiniPure donkey anti-sheep IgG
(Jackson ImmunoResearch Laboratories, West Grove, PA). Binding
was visualized by using ECL Western blotting detection reagents
(Amersham Pharmacia Biotech, Buckinghamshire, England) fol-
lowed by exposure to film. The blot was washed twice, stripped,
and reprobed with anti-rat MAPK RL (ERK1-CT) rabbit polyclonal
IgG primary antibody (Upstate Biotechnology) and anti-rabbit IgG
(peroxidase-linked species-specific whole antibody from donkey;
Amersham Life Science).
Statistics
To determine whether three or more treatment groups were
statistically different, ANOVA (analysis of variance) was per-
formed. Bartlett’s test for homogeneity of variance was followed by
ANOVA. If a significant difference was found, Tukey–Kramer’s
Multiple Comparisons Test was used post hoc.
Developmental rates were expressed as the average proportion
for each experimental replicate. For experiments with only two
variables, statistical significance was calculated by using Fisher’s
Exact Test. For experiments with several variables, individual
proportions from each experimental replicate were arcsine trans-
formed and analyzed by using ANOVA as described above.
In all cases, P  0.05 was considered significant. Descriptive
statistics were obtained by using SigmaPlot (Jandel Scientific, San
Rafael, CA). Throughout, “n” indicates the total number of eggs or
embryos, while “N” indicates the total number of experimental
replicates. Statistical comparisons were done by using InStat
(GraphPad Instat, San Diego, CA).
Digital Photography of Activated Eggs
Activated eggs and embryos were fixed and mounted on slides or
transferred into a coverslip chamber (Harvard Apparatus, Cam-
bridge, MA) containing 10 l microdrops of Hepes–KSOM overlaid
with oil. Images were obtained by using a Zeiss AxioPhot micro-
scope with Phase-contrast optics (40 Nikon PlanApo objective),
equipped with a Sony 3CCD, DXC-390 color video camera with
Northern Eclipse (Empix Imaging Inc., Mississauga, ON) image
analysis software, or a Zeiss IM35 microscope equipped with a Spot
Junior CCD camera (Carl Zeiss Canada, Toronto, ON) and Spot v3.0
software (Spot Diagnostic Instruments Inc., Sterling Heights, MI).
RESULTS
U0126 Parthenogenetically Activates
Unfertilized Eggs
Eggs were cultured in the presence of the MEK inhibitor
U0126 (50 M) for up to 9 h (Fig. 1). A much higher
proportion of unfertilized MII eggs treated with U0126 was
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parthenogenetically activated compared with vehicle-
treated eggs (Fig. 1A). Parthenogenetic activation was sig-
nificantly lower in eggs exposed to the same concentration
of the inactive U0126 analogue, U0124, or to vehicle alone,
compared with activation following exposure to U0126 (Fig.
1B). Both emission of the second polar body and pronuclear
development were induced by U0126 treatment (Fig. 1C)
but with a somewhat slower time course compared with
IVF eggs (Fig. 1D).
After 7–9 h following U0126 treatment, parthenogenotes
were classified on the basis of morphology and assigned to
one of three classes first used by Hirao and Eppig (1997) to
classify parthenogenotes derived from Mos/ oocytes.
Class I included activated eggs that exhibited only second
polar body emission or both pronuclear development and
second polar body emission; Class II included activated eggs
that exhibited abnormal cleavage (large polar body, mul-
tiple blastomeres, and/or incomplete cleavage furrows) or
fragmentation; and Class III included activated eggs that
immediately cleaved to the two-cell stage (Fig. 2). U0126
treatment produced all three phenotypes (Figs. 1A and 2).
Following 8 h of continuous U0126 treatment (50 M),
some parthenogenotes were segregated by class and cul-
tured in standard KSOM microdrop culture. Development
of U0126 parthenogenotes from all three classes was gener-
ally limited to 1–2 additional cleavages within the first 48 h
of culture followed by degeneration (Table 1).
MBP Kinase Is Rapidly Inactivated
upon U0126 Exposure
Upon exposure to U0126 (50 M), MBP kinase activity in
unfertilized eggs fell quickly, and reached half-maximal
activity by 30 min (Figs. 3A and 3C). At 1 h, MBP kinase
activity was very low, comparable to the activity observed
in zygotes. In contrast, MBP kinase activity decreased much
more slowly following IVF, remaining high for at least 3 h
and then becoming gradually inactivated by 7 h post-IVF
(Figs. 3B and 3D). In both cases, eggs cultured in the absence
of U0126 maintained high MBP kinase activity, indicating
that MAPK activity was not affected by our culture condi-
tions.
Active, phosphorylated MAPK protein was not detected
by Western blot using anti-phospho-MAPK antibody in eggs
exposed to U0126 (50 M) for 1 h or in zygotes, but was
clearly present in vehicle-treated eggs (Fig. 4). After the blot
was reprobed by using anti-ERK1 antibody, similar
amounts of MAPK protein were apparent in zygotes, eggs,
and U0126-treated eggs, corresponding to p44ERK1 (upper
band) and p42ERK2 (lower band; Fig. 4). Both bands were
shifted higher in eggs, characteristic of active, phosphory-
lated MAPK. Thus, U0126 exposure results in dephosphor-
ylation and hence inactivation of MAPK in eggs.
MPF Is Inactivated Following MAPK Inactivation
during U0126 Exposure
A double kinase assay for simultaneous measurement of
both histone H1 and MBP kinase activities was performed
on eggs as a function of time of continuous U0126 exposure
or post-IVF treatment to assess the effect of MAPK inacti-
vation by U0126 on MPF activity (Fig. 5). Upon exposure to
50 M U0126 in eggs, MBP kinase activity fell quickly,
reaching basal levels after 1 h (Fig. 5A), consistent with the
results of the assays for MBP activity alone (Fig. 3C).
Histone H1 kinase inactivation was slower than the de-
crease in MAPK activity, reaching half-maximal levels after
FIG. 1. Parthenogenetic activation by the MEK inhibitor U0126.
(A) Average incidence of parthenogenesis measured at 7–9 h of
continuous U0126 (50 M) or vehicle (control) exposure. For
parthenogenetic activation following U0126 treatment, partheno-
genotes were assigned to one of three parthenogenetic classes
(Class I, II, or III) established by Hirao and Eppig (1997). ****
represents statistical significance, P  0.0001; Fisher’s Exact Test.
White bars represent average activation; inset bars (see legend)
represent the proportion of Class I, II, or III parthenogenotes.
Numbers above bars are n(N), where n represents the total number
of eggs and N represents the number of replicates. (B) Average
incidence of parthenogenesis measured in unfertilized eggs treated
with U0126 (50 M), the inactive U0126 analogue, U0124 (50 M),
or vehicle (0.1% DMSO) exposure. Different letters indicate sig-
nificant difference (P  0.05; ANOVA, Tukey–Kramer’s Multiple
Comparisons Test). (C) Average second polar body (PB2; squares)
emission and pronuclear development (PN; circles) in the same
groups of U0126-treated (fF) or vehicle-treated eggs (E). (D)
Average second polar body (PB2-) emission and pronuclear devel-
opment (PN-E) in eggs fertilized in vitro (n  89; N  6).
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1 h and basal levels after about 2 h. Histone H1 kinase
inactivation followed a similar time course in IVF eggs (Fig.
5B). Simultaneously measured MBP kinase activity in IVF
eggs remained high for up to 5 h (Fig. 5B). This is consistent
with the results from the measurements of MBP kinase
alone, which showed that MBP kinase activity was lost
between 5 and 7 h post-IVF (Fig. 3D). Unfertilized eggs
cultured for 5 h maintained high levels of both histone H1
and MBP kinase activities, whereas both histone H1 and
MBP kinase activities were very low in zygotes as expected
(not shown).
Similarly, MBP kinase activity remained elevated in eggs
treated with the inactive U0126 analog, U0124, for 4 h
(129  12%) and in vehicle-treated eggs (115  15%), both
of which were significantly higher compared with U0126-
treated eggs (13 4%; P 0.001; ANOVA; Tukey-Kramer’s
Multiple Comparisons Test). Histone H1 kinase activity
remained elevated after a 4-h exposure to U0124 (144 
13%), which was similar to exposure to vehicle (110 11%;
P  0.05) but significantly different from that measured
after exposure to U0126 (31  16%; P  0.001; ANOVA;
Tukey Kramer’s Multiple Comparisons Test).
It is unlikely that the inactivation of MPF upon U0126
exposure is due to any direct inhibition of MPF activity by
U0126, since activity of kinases including cdk (as well as
MAPK itself) are reported to be unaffected by U0126 (Favata
et al., 1998). In addition, the slower decrease in H1 kinase
activity compared with MAPK inactivation during U0126
exposure (Figs. 3C and 5A) suggests that MPF was not
directly inhibited by U0126. To confirm that U0126 does
not directly inhibit MPF, a double kinase assay was per-
formed on egg lysates with 50 M U0126 included in the
kinase assay mixture, but without exposure of the eggs to
U0126 prior to lysis. Both histone H1 and MBP kinase
activities of egg lysates were high when 50 M U0126 was
present in the double kinase assay mixture, thereby indi-
cating that neither MPF nor MAPK activities were directly
affected by U0126. Mean H1 kinase activity (SEM) was
87 18% and mean MBP kinase activity was 98 5% (N
5; normalized to kinase activities of egg lysates treated with
only the vehicle, DMSO, added to the assay mixtures).
MAPK Inactivation and Parthenogenesis by U0126
Are Similarly Dose-Dependent
Eggs were cultured in 1, 5, or 50 M U0126 and MBP
kinase (MAPK) activity measured at 30 min and 1 h (Fig. 6).
After 30 min or 1 h, MBP kinase activity was significantly
reduced in eggs treated with 50 M U0126 compared with
1 and 5 M U0126 (P  0.05; ANOVA, Tukey–Kramers
Multiple Comparisons Test). Eggs cultured in 50 M U0126
for 1 h had significantly lower MBP kinase activity com-
pared with 1 M (P  0.001) and 5 M U0126 (P  0.01;
ANOVA, Tukey–Kramers Multiple Comparisons Test).
Unfertilized eggs were also cultured for 8 h with 1, 5, 10,
50, or 100 M U0126, and activation was assessed. Parthe-
nogenetic activation of eggs by U0126 after 8 h was dose-
dependent, with activation significantly higher at 50 and
100 M U0126 than at 1, 5, or 10 M (Fig. 7A). Increased
parthenogenetic activation was observed with continuous
U0126 exposure for 24 h compared with 8 h (Fig. 7B), except
at 100 M U0126, which was cytotoxic during prolonged
exposure (81% degenerated following 24 h 100 M U0126
TABLE 1
Long-Term Development of U0126 Parthenogenotes
Cultured by Class
Class n (N)
2 cell
(24 h)
3-4 cell
(48 h)
8 cell
(72 h)
Morula
(96 h)
I 140 (17) 73% 35% 13% 6.0%
II 99 (13) 64% 40% 4% 1.4%
III 11 (3) 78% 27% 7% 0
FIG. 2. Phenotype classes of U0126 parthenogenotes. Unfertilized eggs were exposed to 50 M U0126 for 8 h and assigned to one of three
classes on the basis of morphology. These classes were originally defined to describe the morphology of Mos/ parthenogenotes by Hirao
and Eppig (1997). Class I includes parthenogenotes with pronuclei and/or two polar bodies. Class II parthenogenotes exhibit atypical
divisions and include oocytes with extremely large polar bodies, or oocytes that have undergone fragmentation. Class III parthenogenotes
resemble normal two-cell embryos, with each blastomere containing a visible nucleus (Hirao and Eppig, 1997). PN, pronucleus. Scale bar,
50 m.
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exposure). Again, maximal activation was observed with 50
M U0126.
It is noteworthy that the proportion of U0126-induced
parthenogenotes in each of the Mos/ phenotype classes
varied between experiments. Class III parthenogenotes
were usually present in low numbers. However, the distri-
bution between Classes I and II was variable, with a lower
proportion of Class II sometimes present (e.g., Fig. 1), while
in other groups, the proportion of Class II equaled or
exceeded that of Class I (e.g., Fig. 7A).
Continuous Exposure to U0126 Is Required
to Induce Parthenogenetic Activation
Unfertilized eggs were cultured for 30 min, 2 h, or 8 h
with 50 M U0126 followed by standard KSOM microdrop
culture, with activation assessed at 8 h following initial
introduction of U0126. U0126 activation was dependent on
duration of U0126 (50 M) exposure, while exposure to
vehicle alone had no effect (Fig. 8A). Inactivation of MAPK
upon U0126 exposure was reversible (Fig. 8B). After a 1-h
exposure to U0126, MBP kinase (MAPK) activity increased
within 0.5 h following washout of the drug. This indicates
the need for the continuous presence of U0126 to maintain
low MAPK activity and hence parthenogenetically activate
eggs.
U0126-Induced Parthenogenetic Activation Is
Dependent on an Intact Metaphase II Spindle
and MPF Deactivation
Disruption of the metaphase II spindle has been shown to
maintain metaphase arrest by preventing cyclin destruction
and hence maintaining high MPF activity for an extended
time even after stimuli (e.g., fertilization) which would
FIG. 3. MBP kinase activity following U0126 exposure or IVF. (A) Representative gel showing MBP kinase inactivation following U0126
(50 M) exposure. (B) Representative gel showing MBP kinase inactivation following IVF. The number indicates hours of U0126 exposure
or time post-IVF. “Z” indicates zygotes (negative control). “E-4” and “E-8” indicate eggs cultured for 4 and 8 h, respectively, without
activation. (C) Mean MBP kinase activity ( SEM) following U0126 exposure (F). Mean MBP kinase activity ( SEM) is also shown for eggs
cultured for 8 h in the absence of U0126 (f) and for zygotes (; negative control). (D) Mean MBP kinase activity ( SEM) following IVF
exposure (F). Mean MBP kinase activity ( SEM) is also shown for eggs cultured for 8 h without activation (f) and for zygotes (; negative
control). For both U0126 and IVF, the value of MBP kinase activity of eggs (t  0) was arbitrarily set at 100% with subsequent time points
expressed relative to this amount. Each time point was replicated four to six times.
FIG. 4. Effect of U0126 on the phosphorylation state of endoge-
nous MAPK. Western blot is shown following immunodetection of
MAPK using antibodies specific for phosphorylated MAPK
(pMAPK; top). The blot was subsequently reprobed with anti-ERK1
antibody which cross-reacts somewhat with ERK2 (MAPK; bot-
tom). Lanes are: zygotes (zyg; negative control), eggs (egg; positive
control), and eggs treated with U0126 for 1 h (U0126).
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otherwise activate eggs (Winston et al., 1995). To determine
whether disruption of the metaphase II spindle would
prevent U0126-induced parthenogenesis, eggs were pre-
treated with 1 g/ml demecolcine for 1 h followed by
U0126 activation in the continued presence of demecolcine
for 8–9 h (Fig. 9). We have previously shown that this
concentration of demecolcine both disrupts the spindle and
causes metaphase arrest in oocytes under these conditions
(Phillips and Baltz, 1999). Parthenogenetic activation in-
duced by U0126 was essentially eliminated in the presence
of demecolcine (Fig. 9A), and activation was not signifi-
cantly different from control. Both polar body emission and
pronuclear development were almost completely inhibited
by the presence of demecolcine in U0126-treated eggs (Fig. 9B).
Double kinase assays were performed on eggs pretreated
with demecolcine for 1 h followed by U0126 activation in
the continued presence of demecolcine (as above). In the
presence of demecolcine, histone H1 kinase activity was
maintained at a high level in U0126-treated eggs for at least
4 h, while histone H1 kinase activity in U0126-treated eggs
in the absence of demecolcine fell to basal levels (Fig. 9C).
At 8 h, histone H1 kinase activity in eggs treated with
demecolcine and U0126 had begun to decrease, but was still
significantly higher than histone H1 kinase activity in eggs
treated with U0126 alone. This suggests that the ability of
demecolcine to maintain MPF does not persist indefinitely.
In contrast, MBP kinase activity was reduced to basal levels
by 4 h of exposure to U0126 both in the presence or absence
of demecolcine (Fig. 9D). A Western blot (Fig. 9E) showed
that only the inactive, dephosphorylated form of MAPK
was detectable in eggs treated for 4 h with U0126 either in
the presence or absence of demecolcine (Fig. 9E), confirming
that demecolcine maintained MPF activity, but not active,
phosphorylated MAPK, in the presence of U0126.
Roscovitine Inactivates MPF and Parthenogenetically
Activates Unfertilized Eggs
A much higher proportion of eggs treated with the cdc2
kinase inhibitor roscovitine (50 M) became parthenoge-
FIG. 5. Double kinase assay for simultaneous measurement of
MBP and histone H1 kinase activities following U0126 exposure or
IVF. (A) Mean ( SEM) MBP kinase activity (F) and histone H1
kinase activities () following U0126 exposure. (B) Mean MBP
kinase activity (F) and histone H1 kinase activities () following
IVF. For both U0126 and IVF, the values of MBP kinase and histone
H1 kinase activities of eggs (t 0) were arbitrarily set at 100% with
subsequent time points expressed relative to this amount. Each
time point was repeated four to six times. Kinase activities in
zygotes (negative control) and eggs cultured for 5 h in the absence
of activation were also measured for each replicate (data not
shown).
FIG. 6. Dose-dependent inactivation of MPB kinase following
treatment with U0126. (A) Representative gel showing MBP kinase
inactivation following 1, 5, or 50 M U0126 exposure. U0126
concentrations were as indicated with time post-U0126 (h) shown
below. (B) Mean MBP kinase activity ( SEM) following 1 (E), 5 (u),
or 50 M U0126 exposure (Œ). The value of MBP kinase activity of
eggs (t 0) was arbitrarily set at 100% with subsequent time points
expressed relative to this value. Each time point was replicated four
to six times. * and ** represent statistical significance, P  0.05
and P  0.01, respectively; ANOVA; Tukey–Kramer’s Multiple
Comparisons Test.
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netically activated compared with eggs treated with vehicle
(Fig. 10). Most roscovitine-induced parthenogenotes emit-
ted a second polar body and about half developed a pro-
nucleus, with time courses similar to those following IVF
(compare Fig. 10B with Fig. 1D).
Histone H1 kinase activity, assessed using the double
kinase assay, decreased by roughly 50% after 1 h of expo-
sure to roscovitine, and was completely inactivated before
4 h (Fig. 11). MBP kinase activity, measured simulta-
neously, also declined following roscovitine exposure,
though at a much slower rate, becoming inactivated be-
tween 4 and 8 h (Fig. 11). In contrast, both histone H1
kinase and MBP kinase activities were maintained at a high
level for up to 8 h following exposure to vehicle alone (data
not shown). The time courses for both MPF and MAPK
deactivation by roscovitine were similar to that which
follows IVF (compare Fig. 11 with Figs. 3D and 5B).
It is unlikely that the inactivation of MAPK upon rosco-
vitine exposure was due to direct inhibition of MAPK
activity, since both ERK1 and ERK2 are reported to be
relatively insensitive to roscovitine (Meijer et al., 1997),
and MAPK activity declined only slowly in roscovitine-
treated eggs (Fig. 11). To confirm that roscovitine does not
directly inhibit MAPK, 50 M roscovitine was included in
the double kinase assay mixture with egg lysates. We found
that MBP kinase activity was only slightly affected by 50
M roscovitine, with MBP kinase activity of 74  7%
measured with roscovitine present in the assay mixture
(P 0.01 vs activity in the absence of roscovitine; Student’s
t test; N  5). As expected, the presence of roscovitine in
FIG. 7. Dose-dependent parthenogenesis following treatment
with U0126. Eggs were treated with 1, 5, 10, 50, or 100 M U0126
for 8 (A) or 24 h (B) and assessed for parthenogenetic activation.
Control eggs were similarly cultured with the vehicle for U0126
(vehicle for 5, 50 M: 0.1% DMSO; vehicle for 10, 100 M: 0.2%
DMSO). White bars represent average activation, inset bars (see
legend) represent the proportion of Class I, II, or III partheno-
genotes. Numbers above bars as in Fig. 1. Different letters indicate
significant difference (P  0.05 in (A); P  0.01 in (B); ANOVA,
Tukey–Kramer’s Multiple Comparisons Test).
FIG. 8. Parthenogenetic activation requires continuous exposure
to U0126. (A) Eggs were treated with 50 M U0126 for 30 min, 2 h,
or 8 h followed by culture in the absence of U0126. Parthenogenetic
activation was assessed at 8 h. Control eggs were similarly cultured
in vehicle alone (0.1% DMSO). White bars represent average
activation; inset bars represent the proportion of Class I, II, or III
parthenogenotes bars (see legend). Numbers above bars as in Fig. 1.
Different letters indicate significant difference (P  0.05; ANOVA,
Tukey–Kramer’s Multiple Comparisons Test). (B) Mean MBP ki-
nase activity (SEM) during U0126 exposure (F) and after washout
(E). Arrow indicates removal of U0126. Each time point was
repeated four to six times. The value of MBP kinase activity of eggs
(t  0) was arbitrarily set at 100% with subsequent time points
expressed relative to this amount. MBP kinase activity in zygotes
(negative control) and eggs cultured for 5 h in the absence of U0126
were also measured for each replicate (data not shown).
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the assay mixture inhibited H1 kinase activity, with 27 
7% activity measured when roscovitine was present. This
is comparable to the basal H1 kinase activity in zygotes,
and significantly different from the 100% in egg lysates in
the absence of roscovitine (P  0.001; Student’s t test;
N  5).
Phenotypes of Parthenogenotes Produced
by Roscovitine
We assessed the phenotypes produced when eggs were
activated by roscovitine. Unexpectedly, we found that a
subset of phenotypes was produced after parthenogenetic
activation by roscovitine which was similar to that pro-
duced by U0126 (Fig. 12A), including the large polar bodies
and precocious cleavages (Fig. 12B) typical of Mos/ oo-
cytes. In contrast, eggs activated by IVF (above) or eggs
activated by Sr2 under conditions identical to those used
with roscovitine or U0126 never produced Class II or III
parthenogenotes (not shown).
This implied that normal spindle dynamics and the
cytokinesis which produces the polar body might require
both CSF and MPF activities. We thus assessed the effect of
FIG. 9. Disruption of the metaphase II spindle prevents U0126-
induced parthenogenetic activation. (A) Average incidence of par-
thenogenesis of each class in eggs treated with demecolcine or
vehicle for 1 h, followed by demecolcine  U0126 treatment
(DEME-U0126), vehicle treatment (VEHICLE), or vehicle  U0126
treatment (U0126) for 7–9 h. Concentrations of inhibitors were as
follows: demecolcine 1 g/ml; U0126 50 M and 0.1% DMSO or
ethanol. Different letters indicate significant difference (P  0.01;
ANOVA; Tukey–Kramer’s Multiple Comparisons Test). Numbers
above bars as in Fig. 1. (B) Average second polar body (PB2; squares)
emission and pronuclear development (PN; circles) in DEME-
U0126 (fF), U0126 (uU), or vehicle-treated eggs (E; VEHICLE).
The double kinase assay was used to measure mean histone H1
kinase (SEM; C) and MBP kinase activities (SEM; D) in eggs
treated with demecolcine or vehicle for 1 h, followed by deme-
colcine  U0126 treatment (F) or vehicle  U0126 treatment (U)
for up to 8 h. Each time point was repeated seven times.
* represents statistical significance, P  0.05; Welch’s t test. (E)
Western blot is shown following immunodetection of MAPK by
using anti-ERK1 antibodies which cross-react somewhat with
ERK2. Lanes are demecolcine  U0126 (DEME-U0126), vehicle-
U0126 (U0126), zygote (ZYGOTE; negative control), and vehicle-
treated eggs (VEHICLE).
FIG. 10. Parthenogenetic activation by the cdc2 kinase inhibitor
roscovitine. (A) Average incidence of parthenogenesis measured at
8 h following 50 M roscovitine or vehicle exposure. **** repre-
sents statistical significance, P  0.0001; Fisher’s Exact Test.
Numbers above bars as in Fig. 1. (B) Average second polar body
(PB2; squares) emission and pronuclear development (PN; circles)
in the same groups of roscovitine-treated (fF) or vehicle-treated
eggs (E).
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inhibiting both activities simultaneously, using roscovitine
and U0126 in combination. Cotreatment of eggs with
roscovitine and U0126 produced a majority of Class II-like
phenotypes (Fig. 12A). Most of these eggs exhibited a
pronounced irregular shape with what appear to be incom-
plete cleavages and cleavage furrows (Fig. 12C). Complete
emission of a second polar body was much less frequent in
eggs treated with both roscovitine and U0126 (21%) than in
eggs treated with roscovitine (92%) or U0126 (84%) alone.
Following 8 h of continuous U0126 and roscovitine
cotreatment (50 M each), parthenogenotes were cultured
in standard KSOM microdrop culture. These parthenog-
enotes cleaved at least to the two-cell stage by the next day
(72 17%; n 90, N 6), suggesting that eggs treated with
both U0126 and roscovitine were parthenogenetically acti-
vated and capable of at least some further development
despite the severe phenotype induced by inhibition of both
MEK/MAPK and roscovitine.
DISCUSSION
Inhibition of MEK using U0126 resulted in the loss of
MAPK activity and parthenogenetically activated mouse
eggs. This directly demonstrated a requirement for MEK in
CSF activity in a mammalian egg, confirming their similar-
ity to nonmammalian species such as Xenopus and starfish
(Tachibana et al., 1997; Ferrell, 1999; Abrieu et al., 2001).
This is the first report of complete parthenogenetic activa-
tion by inhibition of MEK in a mammalian egg. However, it
was recently reported that a fraction of porcine oocytes
exposed to U0126 for 20 h underwent partial parthenoge-
netic activation, forming a pronucleus but not cleaving nor
emitting a second polar body (Tatemoto and Muto, 2001).
Indeed, second polar body emission in porcine eggs was
prevented by U0126 even after they were activated electri-
cally.
Development of U0126 parthenogenotes was mostly lim-
ited to one or two cleavages in culture, with no blastocyst
development occurring in any of the three classes (Table 1).
Class I and II parthenogenotes arising from Mos/ oocytes
are also reported to develop poorly, with only about 5%
blastocyst development, while Class III parthenogenotes
fared only slightly better, with 15% development to the
blastocyst stage (Hirao and Eppig, 1997). Thus, the limited
development of U0126 parthenogenotes seen here is consis-
tent with the poor long-term development of Mos/ par-
thenogenotes (Hirao and Eppig, 1997).
We found that the minimum effective U0126 concentra-
tion for both parthenogenetic activation and for inactiva-
tion of MAPK lie within the same range, between 5 and 50
M (Figs. 6 and 7). This supports the hypothesis that both
parthenogenesis and MAPK inactivation by U0126 occur
via a common mechanism of action, in which the decrease
in MAPK activity results in loss of CSF activity and
subsequent MPF inactivation. It should be noted that par-
thenogenetic activation of mouse eggs requires a much
higher concentration of U0126 than the reported IC50 for
inhibition of isolated MEK in vitro (100 nM; Favata et al.,
1998). This is consistent, however, with results obtained in
other cells, in which inhibition of intracellular MAPK
phosphorylation in intact cells by U0126 added to the
medium requires substantially greater concentrations of
U0126 than inhibition of isolated MEK in vitro, probably
due to a lower intracellular concentration of the drug
(Favata et al., 1998; Hoffert et al., 2000), which could arise
from its active export from the cell, intracellular degrada-
tion, or low permeability. We also found that the effect of
U0126 was reversible (Fig. 8B), possibly explaining why
exposure to U0126 for a period substantially less than 8 h
did not effectively activate mouse eggs.
Egg activation by IVF (Figs. 3 and 5; Moos et al., 1995),
cycloheximide (Moos et al., 1996a), ethanol (Verlhac et al.,
1994), or Sr2 (our unpublished data) is characterized by an
initial rapid decrease in MPF activity followed by the more
gradual inactivation of MAPK. In contrast, U0126 inacti-
vates MAPK rapidly and MAPK inactivation precedes MPF
inactivation. While MAPK activity remains high until
about 5 h post-IVF, MAPK was completely inactivated
within 1 h in eggs treated with U0126, and inactivation of
MAPK occurred well before morphological indicators of
parthenogenetic activation were apparent (i.e., emission of
polar body or pronuclear formation). Previous studies have
suggested that high MAPK activity is incompatible with
the formation of pronuclei (Moos et al., 1995, 1996b). If the
converse was true and a decrease in MAPK activity caused
pronuclear formation, we would expect that the rapid
FIG. 11. Double kinase assay for simultaneous measurement of
MBP and histone H1 kinase activities following roscovitine expo-
sure. Mean histone H1 kinase (SEM; F) and MBP kinase activities
(SEM; ) following treatment of unfertilized eggs with 50 M
roscovitine. The value of MBP and histone H1 kinase activities of
eggs (t  0) were arbitrarily set at 100% with subsequent time
points expressed relative to this amount. Each time point was
repeated six to eight times. Kinase activities in zygotes (negative
control) and eggs treated with vehicle were also measured for each
replicate (data not shown).
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inactivation of MAPK which followed U0126 treatment
would have been accompanied by early pronuclear develop-
ment. However, we instead found that pronuclear develop-
ment was somewhat delayed compared with IVF eggs rather
than being precocious. This suggests that, while MAPK
inactivation may play a permissive role in nuclear envelope
FIG. 12. Phenotypes of parthenogenotes following treatment with roscovitine, U0126, or both. (A) Average incidence of parthenogenesis
measured at 8 h following 50 M U0126, 50 M roscovitine, roscovitine in combination with U0126, or vehicle alone. Parthenogenotes
were assigned to one of three parthenogenetic classes as in Fig. 1. Numbers above bars as in Fig. 1. (B) Unfertilized eggs were exposed to
50 M roscovitine for 8 h. I: Class I phenotype with pronucleus (PN) and second polar body (PB2). II: Class II phenotype with very large polar
body (PB2). III: Class III phenotype with two blastomeres, each containing a nucleus (N). (C) Examples of parthenogenotes arising from
unfertilized eggs exposed to roscovitine in combination with U0126 for 8 h. Scale bar represents 50 m.
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assembly, there are other prerequisites for pronuclear for-
mation. These may include decondensation of the meta-
phase chromosomes under the control of MPF. In support of
a role for other checkpoints, we found that disruption of the
metaphase II spindle with demecolcine prevented parthe-
nogenetic activation by U0126 (Fig. 9B) even though MAPK
activity was minimal.
Mouse eggs which were parthenogenetically activated by
U0126 exhibited each of the three phenotypes that arise
from Mos/ oocytes (Hirao and Eppig, 1997). Parthenog-
enotes produced by exposure to U0126 corresponded pri-
marily to Hirao and Eppig’s Classes I and II, with Class III
parthenogenotes that resemble precocious two-cell em-
bryos usually being less common, as previously found for
Mos/ oocytes. Abnormal polar body emission also results
from direct inhibition of MEK during egg activation in
several invertebrate species, including Urechis caupo, oys-
ter, and starfish (Gould and Stephano, 1999; Stephano and
Gould, 2000). Thus, regulation of the cytokinesis which
produces the polar body may be a universal role of MAPK.
The development of Class II and III Mos/ phenotypes
has been proposed to result from dysregulation of mitotic
spindle dynamics in the absence of a functional MOS–
MEK–MAPK pathway. MAPK is associated with microtu-
bule-organizing centers (MTOCs) at the spindle poles as
well as being located in the cytoplasm (Verlhac et al., 1993).
In the Mos/ oocyte, the spindle is elongated and fails to
migrate. Abnormally large polar bodies (Class II) result from
the failure of the spindle to migrate to the periphery, so that
the cleavage furrow forms nearer to the center of the egg
than is normal (Verlhac et al., 2000). Class III partheno-
genotes may represent an extreme situation in which the
cleavage furrow forms at the center of the egg, thereby
producing a parthenogenote resembling a precocious two-
cell embryo. The ability of U0126 to produce each of the
Mos/ phenotypes suggests that loss of MOS activity likely
causes parthenogenesis by the same mechanism as U0126,
namely inhibition of MEK and MAPK.
With Mos/ oocytes, it was not possible to determine the
critical period during which an active MOS–MEK–MAPK
pathway is required for normal spindle function and second
polar body formation in the mouse, since MOS, MEK, and
MAPK activities were absent throughout all of meiotic
maturation. The present work, however, indicates that
MEK and MAPK activity are required specifically during
MII for normal formation of a second polar body, since the
MOS–MEK–MAPK pathway was functional throughout
meiotic maturation and was only disrupted here by U0126
treatment in normal, fully mature MII oocytes.
We have also shown for the first time that direct inhibi-
tion of cdc2 kinase using roscovitine parthenogenetically
activates mouse eggs. Similarly, the related cdk inhibitor,
bohemine, parthenogenetically activates bovine eggs (Albe-
rio et al., 2000), and another related cdk inhibitor, olo-
moucine, has been shown to accelerate pronuclear forma-
tion in mouse eggs activated by other means (Abraham et
al., 1995). Others have previously found that roscovitine
treatment facilitates other means of egg activation in rhe-
sus and mouse eggs, but reported that roscovitine by itself
was unable to activate eggs (Deng and Shen, 2000; Mitali-
pov et al., 2001). We believe that the discrepancy with our
data might be due to the loss of roscovitine from culture
media droplets under oil due to its oil-solubility, since we
only observed parthenogenetic activation of oocytes by
roscovitine when cultured without oil.
Our data showing that inhibition of MPF with roscovi-
tine caused MAPK activity to fall with a time course
essentially indistinguishable from its deactivation after
fertilization support a role for MPF in maintaining CSF
activity in the mouse, complementing the well-known
converse role of CSF in maintaining MPF. This is consistent
with a very recent report that activated cyclin B/cdc2
kinase stabilizes MOS in Xenopus oocytes (Castro et al.,
2001). We hypothesize that the gradual decrease in MAPK
activity that we have shown occurs after inhibition of MPF
by roscovitine reveals the normal physiological mechanism
which governs MAPK deactivation after fertilization,
namely withdrawal of MOS stabilization by MPF. This may
operate in addition to a Ca2-induced increase in MAPK
phosphatase activity, as in the sea urchin (Kumano et al.,
2001).
While many roscovitine-induced parthenogenotes exhib-
ited a second polar body and pronucleus (Class I), a fraction
were Class II and III parthenogenotes indistinguishable
from U0126-induced and Mos/ parthenogenotes (Fig. 12).
It is unlikely that the subset of Mos/-like parthenogenotes
resulting from roscovitine treatment arose by an indirect or
direct effect of roscovitine on CSF activity, since MAPK
was slowly deactivated after roscovitine was introduced
with a time course similar to that following IVF rather than
precociously as with U0126, and inclusion of even 50 M
roscovitine in the double kinase assay, which likely far
exceeds the intracellular concentration in oocytes, only
slightly reduced measured MAPK activity. It is also not
likely to be a nonspecific effect of the culture conditions, as
we never observed parthenogenotes resembling those aris-
ing from Mos/ oocytes with any other means of egg
activation, such as IVF, Sr2, and cycloheximide, even when
the vehicle used for U0126 and roscovitine, DMSO, was
present. Therefore, it appears that inhibition of MPF itself
in MII eggs independently produces some parthenogenotes
with the same phenotypes that arise from disruptions of the
CSF pathway. This is the first report of the development of
Mos/-like phenotypes in parthenogenotes produced with-
out direct disruption of the MOS–MEK–MAPK pathway.
We had originally hypothesized that causing a decrease in
MPF activity using roscovitine before inhibiting MEK and
MAPK activities with U0126 would mimic normal egg
activation and eliminate Class II and III parthenogenotes.
Thus, the appearance of Mos/-like phenotypes following
exposure of MII eggs to the cdc2 kinase inhibitor roscovi-
tine alone was unexpected, since it has been assumed that
the MOS–MEK–MAPK pathway is the main regulator of
spindle function and second polar body cytokinesis (Verlhac
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et al., 1994). Our data, however, support the possibility that
both CSF and MPF activity are required during MII, at least
until cyclin degradation, for normal spindle function and
second polar body cytokinesis. First, Mos/-like partheno-
genotes arose when MPF was inhibited, even though MAPK
deactivation followed its normal postfertilization time
course. Second, the severely disrupted eggs (Class II parthe-
nogenotes and incomplete cleavages) which resulted from
simultaneous inhibition of MPF and CSF activity, indicate
a synergistic effect, which would not be expected if only
CSF activity were required for normal spindle dynamics.
Thus, we propose that normal spindle function and second
polar body emission require that both MPF and CSF be
active until the end of second meiotic metaphase, and that
MPF deactivation must precede that of CSF.
We hypothesize that the premature loss of either CSF or
MPF activity alone partially disrupts spindle function and
cytokinesis, and that either activity is sufficient to permit
the formation of some relatively normal Class I partheno-
genotes. Loss of both activities, however, appears to cause a
much more severe disruption, so that almost all the parthe-
nogenotes produced are Class II and many exhibit incom-
plete cleavages. Further work is needed to compare spindle
and chromatin dynamics, as well as cytokinesis and actin
dynamics, in eggs where CSF, MPF, or both activities have
been disrupted.
In conclusion, we have found that inhibition of MEK in
unfertilized mouse eggs results in parthenogenetic activa-
tion, and that the phenotypes of the parthenogenotes are
nearly identical to those arising from disruption of MOS
during oocyte maturation. The decrease in MAPK activity
occurs rapidly in U0126-exposed eggs, and precedes the
decrease in MPF activity, which occurs with a time course
similar to that in fertilized eggs. It appears likely that
spontaneous parthenogenesis in Mos/ mouse eggs is
solely a consequence of the loss of MEK and MAPK activity
during MII, and that MAPK activity is required for normal
function of the MII metaphase spindle during formation of
the second polar body. We have shown that direct inhibi-
tion of cdc2 kinase in unfertilized mouse eggs also results
in parthenogenetic activation. Surprisingly, a significant
population of roscovitine-induced parthenogenotes exhib-
ited Mos/-like phenotypes. Rapid inhibition of both the
MEK–MAPK pathway and MPF using U0126 and roscovi-
tine in combination resulted in inhibition of cytokinesis.
This suggests that the reduction in MPF and MAPK activi-
ties, as well as the disassembly of the spindle must occur in
a coordinated, step-wise fashion to facilitate the emission of
the second polar body. Thus, a complex interrelationship
between the spindle, MOS–MEK–MAPK pathway, and MPF
seems to regulate emission of the second polar body in
mouse eggs.
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